[go: up one dir, main page]

MX2019006844A - Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña. - Google Patents

Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña.

Info

Publication number
MX2019006844A
MX2019006844A MX2019006844A MX2019006844A MX2019006844A MX 2019006844 A MX2019006844 A MX 2019006844A MX 2019006844 A MX2019006844 A MX 2019006844A MX 2019006844 A MX2019006844 A MX 2019006844A MX 2019006844 A MX2019006844 A MX 2019006844A
Authority
MX
Mexico
Prior art keywords
control
migraine
symptoms
hydroxybutyrates
glyceryl
Prior art date
Application number
MX2019006844A
Other languages
English (en)
Other versions
MX389468B (es
Inventor
Hashim Sami
Original Assignee
Neuroenergy Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroenergy Ventures Inc filed Critical Neuroenergy Ventures Inc
Publication of MX2019006844A publication Critical patent/MX2019006844A/es
Publication of MX389468B publication Critical patent/MX389468B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe un método de control de la reducción y/o la profilaxis y/o el control de los síntomas de migraña mediante el uso de glicéridos de 3-hidroxibutato.
MX2019006844A 2016-12-23 2017-11-30 Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña MX389468B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/389,828 US20180177753A1 (en) 2016-12-23 2016-12-23 Glyceryl 3-hydroxybutyrates for migraine symptom management
PCT/US2017/063832 WO2018118369A1 (en) 2016-12-23 2017-11-30 Glyceryl 3-hydroxybutyrates for migraine symptom management

Publications (2)

Publication Number Publication Date
MX2019006844A true MX2019006844A (es) 2019-08-16
MX389468B MX389468B (es) 2025-03-20

Family

ID=62624821

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006844A MX389468B (es) 2016-12-23 2017-11-30 Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña

Country Status (13)

Country Link
US (2) US20180177753A1 (es)
EP (1) EP3558458B1 (es)
JP (1) JP7108320B2 (es)
KR (1) KR102390608B1 (es)
CN (1) CN110167637B (es)
BR (1) BR112019012431A2 (es)
CA (1) CA3046350C (es)
ES (1) ES2962879T3 (es)
IL (1) IL267540B (es)
MX (1) MX389468B (es)
MY (1) MY190308A (es)
PT (1) PT3558458T (es)
WO (1) WO2018118369A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
FI3558280T3 (fi) 2016-12-21 2023-07-13 Univ Kinderspital Beider Basel Migreenin ennaltaehkäisy ja hoito
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
EP3880641B1 (de) * 2019-01-17 2023-03-15 KetoLipix Therapeutics GmbH Verfahren zur herstellung von glyceriden von hydroxycarbonsäuren
ES2965646T3 (es) * 2019-01-17 2024-04-16 Ketolipix Therapeutics Gmbh Procedimiento para la producción de lípidos que contienen unidades estructurales a base de glicéridos de ácidos hidroxicarboxílicos
IL278422B (en) * 2019-03-14 2022-09-01 Neuroenergy Ventures Inc A flavor masking formulation for ketone body compounds
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US12239624B2 (en) 2019-05-30 2025-03-04 Neuroenergy Ventures, Inc. Glyceryl tris (beta-hydroxybutyrate) and neuronal transient ischemic attacks
EP3956283A1 (de) * 2019-06-12 2022-02-23 IOI Oleo GmbH Verfahren zur herstellung von polyolbasierten estern von acylverkappten 3-hydroxycarbonsäuren
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
IT201900018488A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di preparazione del tris-(3-idrossibutirrato)-gliceril estere
IT201900018491A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di purificazione del tris-(3-idrossibutirrato)-gliceril estere
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
AU2022387742A1 (en) 2021-11-12 2024-06-27 Arxada Ag Polyol-derived compounds
US20250002446A1 (en) * 2021-11-26 2025-01-02 Arxada Ag Acetoacetate Based Ketals
US20240299548A1 (en) * 2022-01-18 2024-09-12 Today, Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
US12023382B2 (en) 2022-01-18 2024-07-02 Today Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
WO2024083889A1 (en) 2022-10-18 2024-04-25 Arxada Ag Polyol-derived compounds
WO2025074001A2 (en) 2023-10-05 2025-04-10 Arxada Ag Enzymatic reduction of acetoacetate
WO2025196156A1 (en) 2024-03-20 2025-09-25 Arxada Ag Continuous hydrogenation process of acetoacetate esters
WO2025224319A1 (en) 2024-04-25 2025-10-30 Arxada Ag Reduction of acetoacetate esters in the presence of amines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420856D0 (en) 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
KR101634083B1 (ko) 2006-04-03 2016-06-28 액세라인크 나이와 관련된 기억 손상의 치료를 위한 케톤 생성 조성물의 용도
US7807718B2 (en) * 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
EA201190115A1 (ru) * 2009-01-24 2012-02-28 ФИТОФАРМ ПиЭлСи Лечение расстройств, опосредованных нейротрофическим фактором
WO2012154837A2 (en) 2011-05-09 2012-11-15 University Of South Florida The use of ketone esters for prevention of cns oxygen toxicity
US20140072654A1 (en) 2011-12-23 2014-03-13 Savind, Inc. Cancer with metabolic therapy and hyperbaric oxygen
FR2997302B1 (fr) * 2012-10-29 2015-02-06 Assist Publ Hopitaux De Paris Prevention et traitement des deficits en pyruvate deshydrogenase
CA2922223C (en) 2012-11-05 2021-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services And Human Services Ketone bodies to protect tissues from damage by ionizing radiation
WO2014085652A1 (en) 2012-11-28 2014-06-05 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
SG11201506780RA (en) * 2013-03-19 2015-10-29 Univ South Florida Compositions and methods for producing elevated and sustained ketosis
GB201314127D0 (en) 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
CA2973342A1 (en) 2014-01-13 2015-10-15 University Of South Florida Methods of sustaining dietary ketosis and its effects on lipid profile
US20160078782A1 (en) * 2014-09-17 2016-03-17 The Trustees Of Boston College Glucose Ketone Index for MetabolicTherapy
US9364456B1 (en) 2015-06-30 2016-06-14 University Of South Florida Ketone esters for treatment of angelman syndrome
WO2017011294A1 (en) 2015-07-10 2017-01-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using medium chain triglycerides, ketone esters, and other ketogenic sources
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
CA3021784A1 (en) 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2018009208A1 (en) 2016-07-08 2018-01-11 Cognate Nutritionals, Inc. Nutritional mitiggation of the cns effects of traumatic brain injury
US20210290581A1 (en) 2016-09-12 2021-09-23 University Of South Florida Neuroregeneration improved by ketone
FI3558280T3 (fi) 2016-12-21 2023-07-13 Univ Kinderspital Beider Basel Migreenin ennaltaehkäisy ja hoito

Also Published As

Publication number Publication date
CN110167637B (zh) 2023-03-14
KR102390608B1 (ko) 2022-04-25
EP3558458A4 (en) 2020-08-12
BR112019012431A2 (pt) 2020-04-14
WO2018118369A1 (en) 2018-06-28
JP7108320B2 (ja) 2022-07-28
CN110167637A (zh) 2019-08-23
US10792269B2 (en) 2020-10-06
CA3046350C (en) 2022-08-16
IL267540A (en) 2019-08-29
ES2962879T3 (es) 2024-03-21
IL267540B (en) 2022-07-01
MX389468B (es) 2025-03-20
MY190308A (en) 2022-04-13
EP3558458A1 (en) 2019-10-30
US20180177753A1 (en) 2018-06-28
KR20190099465A (ko) 2019-08-27
PT3558458T (pt) 2023-11-27
US20190117612A1 (en) 2019-04-25
JP2020502250A (ja) 2020-01-23
CA3046350A1 (en) 2018-06-28
EP3558458B1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
MX2019006844A (es) Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña.
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
AR099153A1 (es) Herramienta de oscilación axial con válvula variable
MX2024004377A (es) Tratamiento mejorado de la dermatitis atopica con tradipitant.
CR20170005A (es) Derivados de insoindolina
MX395060B (es) Sistemas y métodos de control adecuados para el uso con sistemas y métodos de producción de energía.
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
BR112017008856A2 (pt) método para fixar uma coluna de revestimento.
MX2018007123A (es) Control remoto para el control de aparatos mediante la desviacion de la señal de realimentacion del control nativo al control remoto y metodos para el mismo.
BR112019020338A8 (pt) Composição para produção de tagatose, e, método de produção de tagatose
DK3202766T3 (da) Isoxazolderivat som muteret isocitratdehydrogenase 1-inhibitor
UY36221A (es) Derivados de isoindolinona
MX2020009939A (es) Metodos para tratar el sindrome de prader-willi.
PL3683760T3 (pl) Sposób sterowania systemem dostaw energii
DOP2017000085A (es) Derivados estabilizados de adrenomedulina y uso de los mismos
CL2016001192A1 (es) Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX381489B (es) Compuesto biciclico y uso del mismo para la inhibicion de suv39h2.
CL2018003143A1 (es) Compuesto de dihidroisoxazol para uso en el control de piojos de mar
MX2018007121A (es) Control remoto para el control de aparatos mediante la desviacion de la señal de realimentacion del control nativo hacia el control remoto y metodos para el mismo.
ITUA20162376A1 (it) Dispositivo di controllo di un attuatore
MX2019002673A (es) Composiciones y metodos para tratar demencia.
CL2015000305A1 (es) Composición y método para el control de nemátodos fitoparásitos.
DK3524560T3 (da) Elevator med backup-strømforsyning
UY37152A (es) Mutante de corynebacterium glutamicum que produce l-histidina y método para producir l-histidina utilizando el mismo